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Abstract
Background: Patients undergoing surgical aortic valve replacement (sAVR) have high rates of 30-day readmissions.
They also report a low health-related quality of life (HRQOL) and elevated anxiety and depression. The aim of the
AVRre study is to determine the efficacy and cost of a 24/7 phone-support intervention in reducing post-discharge
readmissions after sAVR. The nature of the support is to help patients better understand and self-manage non-urgent
symptoms at home.
Methods/design: AVRre is a prospective, randomised controlled study comprising 30 days of continuous
phone-support intervention and then intermittent follow-up for the first 12 months. Phone call data from and
to patients are evaluated qualitatively; thus, the study has a mixed-method design. Two hundred and eighty-six patients,
aged >18 years, scheduled for a sAVR — singly or in combination with another procedure — are recruited from locations
in southeast Norway. Patients are randomly assigned to the intervention group, who are purposively phone-called
individually 2 and 9 days after discharge and offered on-demand 24/7 (around-the-clock) telephone support
for 30 days post-discharge. The primary outcome variable is the number of 30-day hospital readmissions. Secondary
outcomes are anxiety and depression symptoms, as measured by the Hospital Anxiety and Depression Scale, HRQOL
and quality-adjusted life years, measured by the EuroQol (EQ-5D). Intervention and hospital readmission (diagnosis-
related groups (DRGs)/length of stay) for the first year after initial discharge from hospital are used for a cost-utility
analysis. Standard parametric and non-parametric tests are used for evaluations over time. Analysis of covariance is
used to control for possible differences at baseline. Narratives from phone calls are transcribed verbatim and analysed
using systematic text condensation.
Discussion: A complex ‘around-the-clock’ intervention within a university hospital-based setting could be an effective
strategy to reduce the high readmission rates to hospital after sAVR. Furthermore, the AVRre 24/7 phone-support
manual can be adapted to other high-risk surgery populations with high readmission rates.
Trial registration: ClinicalTrials.gov, NCT02522663. Registered on 11 August 2015.
Keywords: Thoracic surgery, Patient readmission, Clinical trial
* Correspondence: Irene.lie@ous-hf.no
1Centre for Patient-centered Heart and Lung research, Department of
Cardiothoracic Surgery, Division of Cardiovascular and Pulmonary Diseases,
Oslo University Hospital, Building 63, Ullevål, OsloPb 4956, Nydalen 0424, Norway
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lie et al. Trials  (2017) 18:246 
DOI 10.1186/s13063-017-1971-y
Background
Severe aortic stenosis that demands surgical aortic valve
replacement (sAVR) due to considerable morbidity and
mortality is increasing in prevalence as the elderly popula-
tion increases globally [1]. sAVR remains the definitive
treatment for aortic stenosis (AS), and sAVR has an esti-
mated annual incidence of 85,000 cases [1] in the USA
and 1500 cases in Norway (unpublished data from Norwe-
gian Heart Surgery). Irrespective of good immediate surgi-
cal outcomes, sAVR patients are characterised by high
rates of 30-day readmissions to hospital after discharge.
For example, the rates are 19.6% in a US population [2]
and 26% in a Danish population [3], and from unpublished
register data in Norway (Norwegian Patient Registry, AVR
patients’ readmission to hospital, 2011–2014, the Norwe-
gian Directorate of Health 2016), it is estimated to be
22.4% in Norway. Reasons for 30-day readmissions after
sAVR are available in two studies. In an American study,
heart failure, cardiac rhythm disorders, stroke or transient
ischaemic attack, pneumonia, pneumothorax/pleural effu-
sion and gastrointestinal bleeding were reported [4]. In a
Danish study, atrial fibrillation, pericardial effusion, con-
gestive heart failure and pneumonia were the most domin-
ant reasons for 30-day readmissions; these conditions
occurred acutely in 25% of cases [3]. One in five patients
in a study after major surgery was readmitted to a non-
index hospital. The use of an index hospital with specia-
lised competence, versus non-index re-hospitalisation,
resulted in significantly lower in-hospital mortality [5].
Readmission to hospital in Norway is defined as an
unplanned, emergency admittance 8 hours to 30 days
after discharge from hospital, accompanied by at least
one overnight stay with the readmittance [6]. The major-
ity of patients (96%) discharged approximately 1 week
after complex sAVR return home intending to be re-
sponsible for their own physical and mental health and
for arranging follow-up by their general practitioner
(GP) when needed. However, following discharge, pa-
tients/inhabitants and partners experience insecurity and
the psychological and physical burdens associated with
potential readmissions. Moreover, the estimated cost of
readmissions is 2 billion Norwegian kroner (NOK) each
year, with an estimated readmission rate of approxi-
mately 20% [6].
The clinical experience of specialists and municipal
healthcare services reveals that standard care at dis-
charge does not typically include patient education. Two
systematic reviews and meta-analyses of randomised
controlled trials (RCTs) that sought to reduce 30-day
hospital readmissions for different diseases concluded
that no single intervention (e.g. education, telephone
follow-up) was associated with reduced risk for 30-day
re-hospitalisation [7, 8]. For example, Melton et al.
(2012) suggested a two-time telephone follow-up after
discharge during office time [9]. More complex, high-
methodological quality interventions, ones in which pa-
tients are educated and receive support for self-care, are
recommended for preventing hospital readmission and
increasing health-related quality of life (HRQOL) status,
which otherwise is poorly self-reported [3].
Research on readmission after heart surgery highlights
a great need for interventions to be implemented during
the first 30 days after discharge to ensure that patients
receive quality healthcare and engage in safe practices
[3, 5, 10–13]. In a Norwegian home-based intervention
the first month after cardiac surgery (n = 185), patients
and relatives pointed to several negative factors, includ-
ing lack of information at discharge, insecurity and lack
of a ‘connection’ to the index hospital. This was espe-
cially true in the first month after surgery, if complica-
tions such as pleural effusion and arrhythmias appeared
post-discharge [14].
Furthermore, the Norwegian patient experience sur-
veys (2016) report that almost 50% of patients received
incomplete information related to discharge preparation,
especially regarding what symptoms to expect after dis-
charge, and how and whom to contact if complications
occur [15]. These experiences may contribute to feelings
of anxiety in patients. Indeed, approximately 29–61% of
all patients experience moderate to severe levels of anx-
iety and depression during the first month after cardiac
surgery, with symptoms remaining elevated up to
6 months following surgery [16, 17]. These factors de-
serve our attention, because anxiety and depression are
predictors of morbidity and mortality after heart surgery
[18–21]. Therefore, one can hypothesised that interven-
tions that target patients’ and relatives’ need for informa-
tion and follow-up during the first month after cardiac
surgery and the provision of these interventions around
the clock could avoid unnecessary hospital readmissions.
Indeed, a 24/7 follow-up service by phone goes beyond
the results of regular telephone follow-up during office
time. No study has tested the effect of an around-the-
clock follow-up intervention, where the patients’ needs
and symptoms are the base for the intervention. Expert
healthcare professionals will be able to assess worsening
of symptoms on the phone before a critical stage, and
patients can be advised to contact a GP. Telephone
follow-up also allows for inclusion of patients who live a
long distance from both index and non-index hospitals.
This paper presents the detailed protocol for the AVRre
study, in which we aim to determine the efficacy and cost
utility of 30-day around-the-clock, 24/7 phone-support
intervention after discharge for sAVR. The study’s design
and protocol are in accordance with the current Stand-
ard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) guidelines [22]. A SPIRIT
checklist is available online for this manuscript (see
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Additional file 1). Results will be reported following the
CONsolidated Standards Of Reporting Trials (CON-
SORT) guidelines for non-pharmacological interven-
tions [23, 24].
Study objectives
Primary objective
The primary objective of this study is to determine
whether a 30-day, around-the-clock, 24/7 phone-support
intervention reduces the number of hospital readmissions
30 days after discharge from hospital. The intervention be-
gins immediately after initial discharge, and the outcomes
of patients in the intervention are compared to a control
group, which receives usual care.
Secondary objectives
The secondary objectives of the study are as follows:
 To determine whether an around-the-clock, 24/7
phone-support intervention implemented within
30 days after discharge reduces objectively measured
symptoms of anxiety and depression compared to a
control group in the first year after discharge from
hospital
 To determine whether the around-the-clock, 24/7
phone-support intervention implemented within
30 days after discharge improves HRQOL and
quality-adjusted life years (QALYs) compared to the
control group in the first year after discharge from
hospital
 To perform an economic evaluation specifically to
(1) determine the cost utility of the intervention
compared to usual care in the study population and
(2) assess the cost of readmission to hospital and the
cost of GP consultations during the first year after
discharge for the intervention and the control groups
Methods/design
Study design
AVRre is a prospective, randomised controlled trial (RCT),
comprising 30 days of intervention and 12 months of
follow-up. The main study began in August 2015. As the
intervention consists of phone calls from patients to hos-
pital and vice versa, the design of the study includes an ex-
plorative, qualitative component. Thus, this study employs
a mixed-method study design. Supporting material for the
AVRre study is provided in Additional file 2.
Study population, recruitment, randomisation
and follow-up
Patients eligible for study participation are 18 years or
older and are referred for sAVR surgery for the first time
at Oslo University Hospital, at either the Ullevål or Rik-
shospitalet locations, the largest hospitals in southeast
Norway. Consecutively admitted sAVR patients are asked
by project nurses to participate, and they are included if
they meet the following criteria: (1) the surgery is an elect-
ive treatment with a single AVR (biological (b) or mechan-
ical (m), an AVR (b or m) + aortocoronary bypass or an
AVR (b or m) + supracoronary tube graft; (2) the patient
can understand, speak and write the Norwegian language
and (3) can be contacted by phone after discharge from
hospital. Exclusion criteria are the following: (1) the
patient has been admitted to an intensive care unit (ICU)
for more than 24 hours; and/or (2) has complications
related to surgery (e.g. surgery caused cerebral insult with
significant impact on cognitive functions).
One to three days before the planned sAVR, patients
arrive at hospital for preoperative preparations. During
this time, the project nurse informs the patients about
the aim and process of the study. The patients are then
given the informed consent form and the baseline ques-
tionnaires for review and are given time to consider par-
ticipation in the study. Patients are contacted a second
time before surgery to answer any questions about the
study and to deliver further information about the study.
After the patient has provided written informed consent,
patient assignment to either usual care (control) or inter-
vention is accomplished by a web-based randomisation
system developed and administered by the Unit of Applied
Clinical Research, Institute of Cancer Research and Mo-
lecular Medicine, Norwegian University of Science and
Technology, Trondheim, Norway. This system has been
approved by the Data Protection Officer at Oslo University
Hospital as complying with human experimental subject
protections. Randomisation (1:1 ratio) is performed con-
secutively with block randomisation and varying size of the
blocks to make it impossible to predict to which group the
patients are likely to be allocated. Randomisation is done
without stratification to the two cardiothoracic sites of the
study hospital (i.e. Ullevål or Rikshospitalet).
Before standard discharge from the university hospital
to the patient’s local hospital on the fourth day post-
sAVR, the project coordinator (SOD) informs the patient
verbally and in writing (with a leaflet) to which group
he/she has been allocated. For both the control and the
intervention groups, the follow-up assessment takes
place 1 month (T1), 3 months (T2), 6 months (T3) and
12 months (T4) after discharge from hospital. Follow-up
consists of mailing by postal questionnaires with prepaid
stamps for return post after completion (see the patient
flow and data collection chart of Fig. 1).
Usual care
Preoperatively, all patients recommended by a thoracic
surgeon to have aortic valve replacement surgery receive
information on expected HRQOL improvement, longer
life expectancy and possible complications of surgery.
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Currently in Norway, at discharge, there is no standard
information or post-discharge telephone support in
usual care, not from nurses, doctors, university hospitals
or local hospitals. There is no blinding in the study.
Intervention: two components
A brief description of the development of the 24/7
phone-support manual and an example section of it is
available online (Additional file 1). The intervention con-
sists of two components.
Component 1
Patients in the intervention group are purposely called on
days 2 and 9 after discharge by the project coordinator to
proactively assess the patient’s present condition and to
determine if the patient has questions or if problems have
emerged. Details in the patient’s medical history are com-
piled in advance and reviewed prior to the phone calls,
and each structured call relays reminder information to
the patient about the availability of the 24/7 phone-call
service as part of the intervention. The project coordin-
ator emphasises the importance of daily physical activity
[3] and how it has a positive effect on rehabilitation, mor-
bidity and mortality after sAVR. When the patient receives
a Short Message Service (SMS) one day ahead of the
phone call, he/she has the opportunity to respond if the
scheduled day or time is inconvenient for them. Data from
the phone calls will be collected in a written, standard
Fig. 1 Patient flow and data collection chart
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format. Also, patients will be encouraged to relate their in-
dividual responses/experiences/narratives, for example,
when they experience anxiety symptoms.
Component 2
The intervention group is also offered 24/7 around-the-
clock telephone availability during the entire first month
post-discharge. Volunteer, expert intensive care nurses on
duty in a cardiac ICU have been trained by an interdiscip-
linary team to answer the calls from sAVR patients during
the first month after discharge. One aspect that the ICU
nurses make extremely clear is that this 30-day 24/7
phone-support provision is not a replacement for emer-
gency calls to 113 (911 in some countries). For ethical rea-
sons and because of hospital responsibility to the patients,
we include some ’red’ responses (i.e. acute or emergency)
in the manual. However, we expect that the sAVR patients
will call the intervention phone line mostly for non-urgent
health information. If a patient’s problems demand
advanced expertise, the project nurse will consult the
thoracic surgeon or cardiologist on call in hospital to en-
sure that accurate diagnostics are completed and sugges-
tions for treatment are made. The project coordinator is
always available for the ICU nurses to consult, and will
take initiative to arrange regular follow-up meetings and
interdisciplinary discussion of challenging phone calls.
Variables, sources and measurement
Patients will be longitudinally assessed five times during
the course of the project: before sAVR and 1, 3, 6 and
12 months after discharge for sAVR. Additional file 1 in-
cludes a SPIRIT checklist for the schedule of enrolment,
intervention and assessments as presented in Fig. 2. The
written informed consent form for the AVRre study is
included as Additional file 3.
Primary outcome
Readmission
Data from the Norwegian Patient Registry (NPR), the
Norwegian Directorate of Health and patients’ medical
records will be used to gather the numbers of readmis-
sions within 30 days after sAVR discharge. Moreover,
data on causes of readmissions (ICD-10 codes), time and
location (index and non-index hospital) will be collected.
Secondary outcomes
Anxiety and depression symptoms are measured using the
Hospital Anxiety and Depression Scale (HADS) [25, 26], a
Enrolment Allocation Close-out 
TIMEPOINT -t1 
Before surgery
0 
At discharge 
30 days 
24/7 
phone 
support 
t1 
1 month
t2 
3 months
t3 
6 months
t4 
12 months
   tx
ENROLMENT: 
Eligibility screen X  
Informed consent  X  
Allocation  X 
INTERVENTIONS: 
24/7 phone 
support 
Control group X   
ASSESSMENTS
Baseline variable: 
HADS 
EQ-5D 
Comorbidity 
X 
X 
X
Outcome variable: 
Readmissions 
HADS 
EQ-5D 
X X  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X
X 
Fig. 2 SPIRIT schedule of enrolment, interventions and assessments for the AVRre study
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standardised, self-report instrument consisting of 14 items
in two subscales. The 14 items include seven items for
anxiety (HADS-A) assessment and seven for depression
(HADS-D). Patients rate themselves on each item from 0
(not present) to 3 (maximum), yielding a total possible
score of 21 for each subscale. The psychometric properties
of the HADS are well documented in research conducted
in many different countries; this includes valid use in heart
patients [26].
HRQOL and QALY are assessed using the internationally
recognised EQ-5D instrument [27]. EQ-5D is a stan-
dardised instrument comprising five dimensions of self-
reported health status for clinical and economic appraisal.
These dimensions are mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. The respondent
rates himself on each dimension for the degree (no prob-
lem, some problem, extreme problem) that best describes
his/her present health status.
Economic evaluation
Economic analyses are performed for two reasons. (1)
The time it takes to proactively call the patients, as well
as the time needed to answer the patient on the inter-
vention phone and the time needed for calling back if
consulting the physician at hospital, will be measured
and valued. (2) Register data on the cost of readmission
to hospital (diagnosis-related groups (DRGs)/length of
stay) and the number of GP consultations during 30 days
and the first year after discharge will be used for the
cost-utility analysis and will be reported as an incremen-
tal cost-effectiveness ratio (ICER). Sensitivity analyses
will be conducted to measure uncertainty in the esti-
mates. In addition, data from the patients’ medical re-
cords are gathered, e.g. comorbidities.
Data management and statistical analysis
The first and second author have the daily responsibility
for overseeing patient safety, study design, database integ-
rity and study conduct and have access to the final study
dataset. No data will be entered before the intervention is
finalised, to make sure that the baseline data will not influ-
ence the intervention. A random check of at least 20% of
entered data will be performed to ensure data quality be-
fore starting the full data analysis. Data are presented as
means ± standard deviations for continuous variables and
percentages for nominal variables. The primary outcome
variable is measured using the chi-square test to evaluate
group differences. The secondary outcome variables are
measured longitudinally to assess changes over time.
Symptoms of anxiety and depression (HADS) will be ana-
lysed in continuous-form variables before being trans-
formed to a cut-off score ≥8 for anxiety and depression
respectively. We will apply a multilevel logistic model with
the time nested within the patient, and Hosmer’s step-
down procedure [28] to establish a final model. Analyses
will be conducted in R version 3.3.2 (2016-05-03, R Core
Team, 2016) (https://www.r-project.org/). Mixed model
analyses will be applied for repeated measurement of anx-
iety (yes/no) or depression (yes/no) using HADS and EQ-
5D [29]. Analysis of covariance (ANCOVA) is used to test
mean changes between groups, controlling for possible
differences at baseline [30, 31]. A paired sampled t test is
used to analyse mean changes within groups. A statistic
will be considered significant when the corresponding P
value is <0.05. The Statistical Package for Social Sciences
(SPSS), version 21 (released 2012, IBM Corp., Armonk,
NY, USA) is used for statistical analysis.
Missing data
The amount of missing data in the study and the
methods used to handle missing data in the analysis will
be reported [32]. Complete registry data will be available
on primary outcome readmission 30 days after discharge
for sAVR. If a patient dies within 30 days, it will be
counted as readmission. Out of a total sample of 286
sAVR patients, we estimate 0–2 deaths. These numbers
will not influence the power of the study. Regarding
secondary outcomes, the guidelines in the article of
Little et al. [32] will be followed; hence, we will perform
multiple imputation analyses in analyses where missing
data are not handled properly otherwise. In addition,
sensitivity analyses will be performed to assess the ro-
bustness of assumptions made.
Narrative data analysis
Data/narratives from patients’ phone calls to hospital and
project coordinator phone calls to patients
All qualitative data are transcribed verbatim and ana-
lysed in several steps using systematic text condensation
in accordance with the approach of Malterud [33]. Ex-
perts in qualitative analysis in the research group re-
sponsible for the AVRre study will re-read the narratives
independently before the subsequent data reduction into
meaning units, condensed meaning units, subthemes
and themes guided by the study’s aim.
Mixed methods
Qualitative data as narratives from the patients are intended
to complement and enrich the quantitative data from study
measures. Using narratives from patients’ phone calls will
focus on the spontaneous needs and symptoms from the
patients’ perspective, thus avoiding recall bias that may
occur during interviews at a later time. The two approaches
are planned to be used in tandem to answer the research
questions in this study [34]. One challenge that needs to be
figured out is how to interpret conflicting results.
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Sample size and power calculation
In 2013, a total of 503 patients had aortic valve replace-
ment surgery at Oslo University Hospital. To estimate
the sample size required to make confident conclusions
about the primary outcome — the number of readmis-
sions 30 days after discharge from hospital — we used
published data on readmissions in Norway for patients
>65 years old. Seventeen percent of the patients are re-
admitted to hospital within 30 days from discharge [6].
A sample size of 286 patients with 143 patients in each
group will achieve at least 80% power to detect an ex-
pected difference of 15% in the control group and 5% in
the intervention group at the 5% significance level using
the chi-square test.
Ethical considerations: ethics and disseminations
The study is conducted in accordance with the Declar-
ation of Helsinki. Ethical approval was obtained from the
Regional Committees for Medical and Health Research
Ethics (approval 2013/2031-3). All patients receive both
verbal and written information about the aim of the study
and are informed that they are free to withdraw from the
study at any time. Patients sign an informed consent
document prior to inclusion. The codebook with study
numbers and person-sensitive information and data from
phone calls is kept in a locked, firewall-secured cabinet.
To be able to perform the cost-utility analysis, we in-
cluded in the written, informed consent form the patients’
permission to collect person-identifiable sensitive data
from the medical record and from the Patient Registry
Department at the Norwegian Directorate of Health. The
results are presented so that the identity of the subjects
cannot be identified, either directly or from derived infor-
mation. Results from this study will be published in peer-
reviewed journals.
Discussion
This randomised controlled study, which we call AVRre, is
the first programme to offer and test the effectiveness of a
complex 24/7, around-the-clock intervention to optimise
sAVR patients’ safety and healthcare in the vulnerable re-
admission phase 30 days after discharge. The intervention
is complex, because phone calls are made proactively to
the patient 2 and 9 days after discharge, and because tele-
phone support from expert healthcare professionals is
made available day, evening and night during the first
30 days after hospital discharge. Combining experimental
and explorative approaches results in mixed-method data,
which will strengthen the conclusions we can draw and
produce more solid information about sAVR patients’ ex-
periences at home.
Analyses of patient narratives about the symptoms
they experience and their needs during early rehabilita-
tion will produce new insights for developing effective
patient information systems and education programmes
relevant for sAVR patients in the future. Moreover,
symptom monitoring combined with evidence-based
and clinical expertise advice can accommodate patients’
desires to feel secure and to submit their requests for
information after discharge from hospital [14]. More-
over, as we have hypothesised, this should reduce the
number of 30-day hospital readmissions and reduce
symptoms of anxiety and depression. Readmissions
after sAVR are sparsely documented in the research lit-
erature, and reports of readmissions in RCTs, except
for a few registry studies/observational studies, are al-
most unknown [8].
Mixing both quantitative and qualitative methods in
this RCT increases the probability of obtaining valuable
empirical knowledge from sAVR patients in addition to
evidence of treatment effect [34]. First, triangulation
generated by different data sources is possible; e.g. sup-
pose a patient in the intervention group has a high score
for anxiety on HADS, and that patient calls the AVR 24/
7 phone to elaborate on and get advice for a case he felt
anxious about after sAVR. This would validate informa-
tion that stems from the instrument.
Prevention of missing data to increase the representa-
tiveness of the sample in this trial is related to both de-
signing and conducting the trial [32]. In designing the
intervention, former patients and interdisciplinary spe-
cialists in the cardiac field revealed the themes for the
intervention manual and 24/7 follow-up after discharge,
in accordance with evidence-based literature. Moreover,
the intervention is flexible, as it is based on when the
patients need support. The patients in the control group
receive information at discharge about group allocation
and the importance of comparing the intervention and
the control group in order to offer future sAVR patients
a solid follow-up based on patients’ needs. When con-
ducting the study, the participants’ burden and incon-
venience of data collection is limited to only two
questionnaires with a few items, to avoid missing values
and drop-out. The project coordinator is dedicated to
follow up the participants and the expert nurses respon-
sible for the 24/7 intervention to limit missing data in
the conduct of the study. It is time-consuming to carry
out a 24/7 phone support service, and it requires expert
healthcare professionals to be deeply and continuously
motivated to seriously carry out the study. This is an on-
going challenge, and it is necessary to safeguard the
strength of the study. The intervention is bolstered by
experiencing and discussing patient cases and by the
teaching of relevant themes during the intervention
period. Moreover, assessment of the intervention’s cost
utility will provide valuable information for the health-
care system to develop ways to improve the transition of
patient care to reduce readmissions [35]. Furthermore,
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knowledge from this study may add valuable information
to optimize healthcare for future comparison to the
emerging transcatheter aortic valve implantation (TAVI)
patient population.
Insight into an individual patient’s pathway through
the readmission process is made possible for the first
time by patients’ agreeing to allow researchers to gain
access to register data. A normal pathway for a patient
undergoing sAVR is to be transferred from an index,
specialised hospital to a non-index hospital with a lower
level of care at the fourth day after surgery. Fragmented
care, which can occur when patients are transferred be-
tween hospitals at different levels in healthcare systems,
increases the risk of mortality [5] and is a present chal-
lenge for patients and the healthcare system. This study
is limited in that it includes patients only at one univer-
sity hospital with two departments.
Before surgery, the patients are informed about the ex-
pected increase in health status after surgery. Adding
the QALY analysis takes into account both the quantity
and quality of life generated by healthcare intervention
and may add valuable preoperative information for
future patients undergoing sAVR.
The lack of masking in this study related to patients
may have a potential influence on outcomes [24]. Patients
are informed about group allocation 1–2 days before dis-
charge from the University Hospital. If a patient from the
control group and one from the intervention group by
coincidence are in the same room, the project nurse has
organised separate information about further follow-up in
the study. The patient in the intervention group is encour-
aged not to share information about the intervention. The
general information of the ongoing AVRre study at the
Department might influence the patient in the control
group and the caregivers, e.g. to offer more information
than usual care and possibly threaten internal validity
(the Hawthorne effect).
In conclusion, the knowledge gained from this study
will provide valuable insights for adjusting aspects of the
healthcare system now to improve care for patients
undergoing sAVR and will inform future studies on
sAVR. The 24/7 phone-support manual has the potential
to be modified and adopted for use by other surgical
populations with high readmission rates.
Trial status at the time of initial manuscript submission
Recruitment for this trial is ongoing.
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